Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 12:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Multiple Sclerosis, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases, Autoimmune Diseases, Immune System Diseases, Pathologic Processes
Interventions
Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test, T-Detect COVID T-cell blood test
Device
Lead sponsor
Dragonfly Research, LLC
Other
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Wellesley, Massachusetts
Conditions
Multiple Sclerosis, Covid19
Interventions
Not listed
Lead sponsor
St. Barnabas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Livingston, New Jersey
Conditions
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
23
States / cities
Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Acute Ischemic Stroke
Interventions
natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 13 more
Conditions
Multiple Sclerosis
Interventions
Natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
1,615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Multiple Sclerosis
Interventions
Diroximel Fumarate, Avonex, Tysabri, Dimethyl Fumarate
Drug · Biological
Lead sponsor
Biogen
Industry
Eligibility
Female only
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
2
States / cities
Aurora, Colorado • Durham, North Carolina
Conditions
Rheumatoid Arthritis
Interventions
natalizumab, placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
10
States / cities
Birmingham, Alabama • Tucson, Arizona • Escondido, California + 7 more
Conditions
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Multiple Sclerosis
Interventions
Hematopoietic Stem Cell Therapy, Standard treatment with a conventional drug
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
natalizumab, fingolimod
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
12
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Port Charlotte, Florida + 9 more
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
11
States / cities
Los Angeles, California • Hartford, Connecticut • Miami, Florida + 7 more
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA
Interventions
Anal Pap smear and HPV DNA testing
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 85 Years
Enrollment
310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Rocky Mountain MS Research Group, LLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Multiple Sclerosis
Interventions
Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Multiple Sclerosis
Interventions
Natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Latham, New York
Completed No phase listed Observational

JC-Virus (JCV) Antibody Program

NCT01070823
Conditions
Multiple Sclerosis
Interventions
Tysabri® (natalizumab)
Drug
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
1,096 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • Cullman, Georgia + 8 more
Completed Phase 2 Interventional Results available

Natalizumab High Titer Immunogenicity and Safety

NCT00516893
Conditions
Multiple Sclerosis
Interventions
BG00002-E (natalizumab high titer)
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Washington D.C., District of Columbia • Maitland, Florida • Miami, Florida + 10 more
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
natalizumab
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
44
States / cities
Homewood, Alabama • Sun City, Arizona • La Jolla, California + 39 more
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Rocky Mountain MS Research Group, LLC
Other
Eligibility
18 Years to 80 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Crohn's Disease, Prenatal Exposure, Multiple Sclerosis, Pregnancy
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Sickle Cell Disease
Interventions
Motixafortide, Natalizumab, Leukapheresis
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Relapsing Multiple Sclerosis
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
35,895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
473
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucaloosa, Alabama + 386 more